1. Home
  2. Research
  3. Research Groups
  4. Surgical research in urology and renal trasplantation

Surgical research in urology and renal trasplantation

Search for publications

Only original articles, editorials, guidelines.

  • Krajewski W, Nowak L, Laszkiewicz J, Chorbinska J, Tomczak W, Gurwin A, Moschini M, Pradere B, Gallioli A, Subiela JD, Laukhtina E, Del Giudice F, Marcq G, Afferi L, Krajewska M, Khan MS, Nair R, Malkiewicz B, Szydelko T.

    Impact of Histological Subtypes/Divergent Differentiation on Clinicopathological and Oncological Outcomes for Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Comprehensive Updated Systematic Review and Meta-analysis.

    European Urology Oncology . 8(4): 1126-1139.

    [doi:10.1016/j.euo.2025.03.003]

  • Araujo-Castro M, Mínguez Ojeda C, Gómez Dos Santos V, Sanjuanbenito A, Gómez Ramírez J, Mercander E, Hanzu F, Zarain L, Vidal Ó, Muriel García A, Artiles Medina A.

    Surgical outcomes of partial adrenalectomy for pheochromocytoma: A systematic review and meta-analysis.

    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS . 26(4): 625-640.

    [doi:10.1007/s11154-025-09962-9]

  • Jimenez-Fonseca P, Álvarez-Escola C, Ballester Navarro I, Hernando Cubero J, González Fernández L, Mangas Cruz MÁ, Iglesias C, García-Donas J, Picón MJ, Paja M, González Batanero L, García L, Molina J, Jimeno Maté R, Aller J, Romero MDCT, Cardenas Salas J, Gutiérrez-Buey G, Egaña Zunzunegui N, Navarro M, Lecumberri MJ, Valdés N, Carmona-Bayonas A.

    External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy.

    EUROPEAN JOURNAL OF ENDOCRINOLOGY . 193(2): 320-328.

    [doi:10.1093/ejendo/lvaf171]

  • Bourlon MT, Galli L, Grande E, Park SH, Melichar B, Schieber TJ, Juan-Fita MJ, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, De Giorgi U, Kucharz J, Pérez Calabuig E, Conteduca V, Taha T, Rescigno P, Abu-Sini H, Spinelli GP, Manneh Kopp R, Salfi A, Bhuva D, Valdez-Sandoval P, Mendez-Bribiesca S, Fiala O, Buti S, Marques Monteiro FS, Bamias A, Ghosn M, Massari F, Ansari J, Santoni M.

    Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.

    Frontiers in Oncology . 15: 1605282-1605282.

    [doi:10.3389/fonc.2025.1605282]

  • Manneh R, Molina-Cerrillo J, de Velasco G, Ibatá L, Martínez S, Ruiz-Granados Á, Alonso-Gordoa T.

    PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis.

    PHARMACEUTICALS . 18(7): .

    [doi:10.3390/ph18071015]

  • Rizzo M, Soares A, Gupta S, Calabrò F, Takeshita H, Bourlon MT, Park SH, Giannatempo P, Myint ZW, Büttner T, Grande E, Fiala O, Santini D, Bamias A, Zakopoulou R, Buti S, Kanesvaran R, Rescigno P, Molina-Cerrillo J, Epstein I, Marques Monteiro FS, Massari F, Porta C, Bellmunt J, Santoni M.

    Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

    Jco Global Oncology . 11: .

    [doi:10.1200/GO-24-00564]

  • López Curtis DA, Artiles Medina A, Subiela JD, Fernández-Mardomingo Díaz A, González Tello F, Muriel García A, de la Parra Sánchez I, Mínguez Ojeda C, Jiménez Cidre MÁ, Gómez Dos Santos V, Burgos Revilla FJ.

    Revisiting angiomyolipomas: The significance of a rich blood supply on imaging for risk-adapted decision making.

    Investigative and Clinical Urology . 66(4): 285-294.

    [doi:10.4111/icu.20250059]

  • Mínguez Ojeda C, Artiles Medina A, Fraile Poblador A, Sánchez González Á, Subiela Henríquez JD, Brasero Burgos J, de la Parra Sánchez I, López Curtis D, Del Olmo Durán P, Fernández-Mardomingo Díaz A, Jiménez Cidre MA, Gómez Dos Santos V, Burgos Revilla FJ.

    Analysis of device survival and predictive factors of failure in a cohort of patients with male artificial urinary sphincter.

    Actas Urologicas Espanolas . 49(6): 501786-501786.

    [doi:10.1016/j.acuroe.2025.501786]

  • Scilipoti P, Longoni M, de Angelis M, Zaurito P, Slusarczyk A, Soria F, Pradere B, Krajewski W, D'Andrea D, Mari A, Del Giudice F, Pichler R, Subiela JD, Marcq G, Gallioli A, Afferi L, Mastroianni R, Simone G, Albisinni S, Mertens LS, Laukhtina E, Oberneder K, Rodríguez Elena JL, Aranda J, Puentedura AL, Caño Velasco J, Contieri R, Hurle R, Mori K, Radziszewski P, Shariat SF, Gontero P, Necchi A, Rouprêt M, Montorsi F, Salonia A, Briganti A, Moschini M.

    Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer.

    BJU INTERNATIONAL . 136(1): 47-54.

    [doi:10.1111/bju.16675]

  • Carnero-Alcázar M, Nuñez-Gil IJ, Vilacosta I, Montero L, Cuerpo G, Lopez-Menendez J, Feltes-Guzman G, Beltrao-Sial R, Pérez-Camargo D, Vicedo-López Á, Miranda-Torrón J, Solís-Chávez MB, Cobiella J, Maroto L.

    Need for a permanent pacemaker after transcatheter aortic valve implantation in Spain: a retrospective analysis of the national Minimum Basic Dataset from 2017 to 2022.

    Open Heart . 12(1): .

    [doi:10.1136/openhrt-2025-003396]

  • Pichler R, van Creij NCH, Subiela JD, Cimadamore A, Caño-Velasco J, Tully KH, Mori K, Contieri R, Afferi L, Mari A, Soria F, Del Giudice F, D'Elia C, Mayr R, Mertens LS, Pyrgidis N, Moschini M, Gallioli A.

    Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease.

    Actas Urologicas Espanolas . 49(5): 501719-501719.

    [doi:10.1016/j.acuroe.2025.501719]

  • Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M.

    Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.

    BJU INTERNATIONAL . 135(6): 969-976.

    [doi:10.1111/bju.16645]

  • Albers Acosta E, Pelari-Mici L, Celada Luis G, Velasco Balanza C, Zapatero A, Romero-Laorden N, Toquero Diez P, Caño-Velasco J, Guerrero-Ramos F, Moschini M, Krajewski W, Del Giudice F, Soria F, Laukhtina E, Mertens L, Pichler R, Mori K, D'Andrea D, Mari A, Marcq G, Teoh J, Afferi L, Albisinni S, Pradere B, Gallioli A, Subiela JD, San José Manso L.

    The impact of a multidisciplinary approach on treatment decisions and outcomes in urothelial carcinoma: A systematic review.

    Actas Urologicas Espanolas . 49(5): 501718-501718.

    [doi:10.1016/j.acuroe.2025.501718]

  • Santoni M, Roviello G, Grande E, De Giorgi U, Fiala O, Seront E, Molina-Cerrillo J, Pichler R, Myint ZW, Kucharz J, Kanesvaran R, Büttner T, Pichler M, Basso U, Kopecky J, Bourlon MT, Cerbone L, Buchler T, Pinto A, de Liaño AG, Gianni C, Zgura A, Rescigno P, Ansari J, Caffo O, Küronya Z, Vitale MG, Bhuva D, Catalano M, Vau N, Kopp RM, Buti S, Bamias A, Porta C, Sunela K, Massari F.

    Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(7): 225-225.

    [doi:10.1007/s00262-025-04043-x]

  • Gómez Rivas J, de la Parra I, Infante S, Ibañez L, Gutierrez Hidalgo B, Cabrera MN, Puente J, Sanmamed N, Ortega Polledo LE, Galante MI, Moreno Sierra J.

    Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era.

    MEDICINA-LITHUANIA . 61(5): .

    [doi:10.3390/medicina61050924]

  • Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, Ürün Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M.

    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(7): 196-196.

    [doi:10.1007/s00262-025-04019-x]

  • Alonso-Gordoa T, Anguera G, Domínguez-Esteban M, Reig Ò, Martínez-Barros H, Molina-Cerrillo J, Cruz P, Maroto P.

    Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies.

    CANCER TREATMENT REVIEWS . 136: 102925-102925.

    [doi:10.1016/j.ctrv.2025.102925]

  • Rodríguez-Moreno JF, de Velasco G, Álvarez-Fernández C, Collado R, Fernández R, Vázquez S, Virizuela JA, Gajate P, Font A, Lainez N, Sevillano-Fernández E, Graña-Castro O, Beltrán L, Madurga R, Rodríguez-Antona C, Berraondo P, Ruiz-Llorente S, García-Donas J.

    Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

    CLINICAL CANCER RESEARCH . 31(9): 1644-1656.

    [doi:10.1158/1078-0432.CCR-24-2890]